Tamiflu slumps but oncology strong for Chugai
This article was originally published in Scrip
Executive Summary
Overall revenues at Roche's Japanese subsidiary, Chugai, slipped by 8% to ¥87.1 billion ($924.6 million) in the first quarter to 31 March, hit by a sharp drop in sales of Tamiflu (oseltamivir).